期刊文献+

IFN-γ对血管内膜损伤后平滑肌细胞增殖和内膜形成的影响 被引量:4

暂未订购
导出
摘要 目的:为临床应用γ干扰素(IFNγ)防治经皮冠状动脉成形术后再狭窄提供理论依据。方法:建立兔髂动脉再狭窄动物模型,动态观察体内给予重组γ干扰素(rIFNγ)对血管内膜平滑肌细胞(vSMCs) 增生和内膜形成的抑制作用。结果:rIFNγ可显著抑制1 周和2 周时内膜面积,抑制率分别为60-00% 和66-67% ;抑制1 周和1 个月时内膜vSMCs 表达增殖细胞核抗原,抑制率分别为88-50% 和58-89% 。结论:IFNγ通过抑制vSMCs 的增生减少内膜的形成并可能用于临床防治再狭窄。
出处 《实用医学杂志》 CAS 2000年第1期9-11,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献9

  • 1袁晋青.分子生物学与经皮冠状动脉腔内成形术后再狭窄的预防[J].中国循环杂志,1996,11(11):697-700. 被引量:7
  • 2钱济先,钱兆奇.γ干扰素抑制血管平滑肌细胞增殖[J].国外医学(创伤与外科基本问题分册),1998,19(3):146-148. 被引量:3
  • 3MorimotoS,MizunoY,HiramitsuS,etal.RestenosisafterPTCA-ahistopathologicalstudyusingautopsiedhearts.JpnCircJ,1990,54:43~56.
  • 4WilcoxJN.Molecularbiology:Insightintothecausesandpreventionofrestenosisafterarterialintervention.AmJCardiol,1993,72:88~95E.
  • 5ShimokadoK,YokotaT,KatoN,etal.BidirectionalregulationofsmoothmusclecellproliferationbyIFN-gamma.JAtherosclerThromb,1994,(suppl1):29~33.
  • 6SirsjoA,SoderkvistP,SundqvistT,etal.DifferentinductionmechanismsofmRNAforinduciblenitricoxidesynthaseinratsmoothmusclecellsincultureandinaorticstrips.FEBSLett,1994,338(2):191~196.
  • 7BeasleyD,McguigginM.Interleukin1activatessolubleguanylatecyclaseinhumanvascularsmoothmusclecellsthroughanovelnitricoxide-independentpathway.JExpMed,1994,179(1):71~80.
  • 8WamerSJC,FiedmanGB,LibbyP.Immuneinterferoninhibitsproliferationandinduce2'-5'-oligoadenylatesynthetasegeneexpressioninhumanvascularsmoothmusclecells.JClinInvest,1989,83:1174~1182.
  • 9SasamuraH,ZakazatoY,HayashidaT,etal.Regulationofvasculartype1angiotensinreceptorsbycytokines.Hypertension,1997,30(1pt1):35~41.

二级参考文献2

  • 1Shi Y,Circulation,1994年,90卷,944页
  • 2Shi Y,Circulation,1993年,88卷,1190页

共引文献8

同被引文献30

  • 1刘长茹,刘国萍,李彩霞.γ-干扰素雾化吸入治疗婴幼儿毛细支气管炎临床研究[J].临床荟萃,2002,17(21):1270-1271. 被引量:1
  • 2袁晋青.分子生物学与经皮冠状动脉腔内成形术后再狭窄的预防[J].中国循环杂志,1996,11(11):697-700. 被引量:7
  • 3龚国忠 郑宣鹤 等.Ib型丙肝病毒在外周血单核细胞感染状态及其对IFN应答的影响[J].中华微生物和免疫,1998,18(6):452-454.
  • 4[1]Baron S, Tyring S K, Fleischmann W R, et al. The interferons : mechanisms of action and clinical applications. JAMA, 1991,266(10): 1375~ 1383
  • 5[2]Comell R C,Greenway H T,Tucker SB,et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad De rmatol,1990,23(4 pt) :694~700
  • 6[3]Perrillo R P,Schiff E R,Davis G L,et al. A randomized controlled trial of interferon alpha- 2b alone and after prednisone with drawal for the treatment of chronic hepatitis B. N Engl J Med,1990,323(5):2955~301
  • 7[4]Marelli A, Nardecchia L, de Gennaro F,et al. Therapy of chronic hepatitis C with alpha- interferferon in 182patients. evaluation of results, response predictive factors and side effectsp. Minerva Med,1999,90(11- 12) :405~412
  • 8[5]Omata M, Yokosuka O, Takano S,ea al. Resolution of actute hepatitis C after therapy with natural betainterferon. Recent Prog Med, 1998,89 (5): 55~ 62
  • 9[6]Vezzoli M ,Girola S,Fossati G ,et al. Beta- Interferon the rapy of chronic hepatitis HCV +, lb genontype. Recent Prog Med ,1998,89(5) :235~240
  • 10[7]Di Bisceglie AM,Rustgi VK,Kassianides C,et al. Therapy of chronic hepatitis B with recombiant human alpha and gamma interferon. Hepatology, 1990,11 (2) .. 266 ~ 270

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部